Zepbound sales double, tariffs could hit Ozempic, and Pfizer on RFK Jr.: Pharma news roundup

Ozempic is medicine for adults with type 2 diabetes . Wegovy is prescribed for long-term weight loss in adults and children. Both contain the active ingredient semaglutide, on January 13, 2025, in Sydney, Australia.

Image: Steve Christo – Corbis / Contributor (Getty Images)

Novo Nordisk, the maker of the popular GLP-1 medications Wegovy and Ozempic, said potential tariffs on Europe imposed by U.S. President Donald Trump could affect its business. Novo Nordisk CEO Lars Fruergaard Jørgensen told reporters during a press conference Wednesday that the company was “not immune” to potential tariffs. Still, he remains confident that the Danish pharma giant is in a “good position to meet the demands of the new [U.S.] administration.”

Zepbound sales double, tariffs could hit Ozempic, and Pfizer on RFK Jr.: Pharma news roundup

Similar Content

Leave a Reply Cancel reply